A study explored outcomes among patients living with newly diagnosed eosinophilic esophagitis (EoE) who demonstrated lack of histological response following proton pump inhibitor (PPI) treatment.
NorthSea Therapeutics B.V.: Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients
Interim readout based on the first 90 patients treated for 16 weeks
Once-daily oral icosabutate showed dose-dependent, significant, and clinically meaningful improvements in all liver function chemistry, and inflammatory and fibrotic biomarkers with a remarkable reduction of over 50% in hsCRP
Lipid profile and glycemic control showed significant improvements
Blinded safety data show a benign safety profile reviewed regularly by the DSMB
NorthSea Therapeutics B.V., ( NST ) a Dutch biotech company developing novel and innovative therapies for NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory, and fibrotic diseases based on its SEFA (Structurally Engineered Fatty Acid) technology, today announced a positive interim readout of its ICONA Phase 2b study.